Drugs / Methoxyflurane
Methoxyflurane
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PENTHRANE | — | 1962-05-04 | fda.gov ↗ |
Trials 27 · a red edge is where a trial was stopped
19611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07192198 | Apr → Nov 2024 | hematocele of tunica vaginalis testis, hydrocele, scrotal disorder, spermatocele | University of Manitoba | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07445737 | Jun 2026 → Jun 2029 expected | ST-elevation myocardial infarction | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07017452 | Aug → Dec 2025 overdue | benign prostatic hyperplasia | University of Manitoba | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06495372 | Oct 2024 → Oct 2025 | tooth disorder | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT05137184 | Nov 2021 → Apr 2023 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04618497 | Oct → Nov 2020 | — | Hospital Authority, Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT04476173 | Jun 2020 → Jun 2024 | ST-elevation myocardial infarction, acute coronary syndrome | Collegium Medicum w Bydgoszczy | Unknown | No outcome recorded |
| Phase 3 | NCT03585374 | Feb 2018 → Feb 2019 | — | Mundipharma Pharmaceuticals srl | Completed | No outcome recorded |
| Phase 3 | NCT03215056 | Aug 2017 → Jun 2022 | — | Medical Developments International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03256903 | Jul 2017 → Mar 2018 | — | Mundipharma Pharmaceuticals S.L. | Completed | No outcome recorded |
| Phase 3 | NCT02604225 | Dec 2015 → Dec 2019 | cancer | University of Sydney | Completed | No outcome recorded |
| Phase 3 | NCT01420159 | Aug 2011 → Jul 2012 | — | Medical Developments International Limited | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT07295054 | Apr → Dec 2026 expected | — | Women's College Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06392087 | Aug 2024 → Mar 2025 overdue | — | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05821517 | Dec 2023 → Dec 2026 expected | — | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 4 | NCT05766397 | Sep 2023 → Jul 2024 overdue | occupational disorder | Ottawa Hospital Research Institute | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04287803 | Apr → Nov 2021 | — | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT04442919 | Jun 2020 → Jan 2024 | intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT04412642 | May → Sep 2020 | acute pyelonephritis | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| Phase 4 | NCT04029012 | Sep 2019 → Feb 2020 | benign prostatic hyperplasia | Dean Elterman | Completed | No outcome recorded |
| Phase 4 | NCT03849027 | May → Sep 2019 | — | University of Cape Town | Unknown | No outcome recorded |
| Phase 4 | NCT03868436 | Apr 2019 → Mar 2020 | — | Purdue Pharma, Canada | Completed | No outcome recorded |
| Phase 4 | NCT03798899 | May → Dec 2018 | — | Mundipharma SAS | Completed | No outcome recorded |
| Phase 4 | NCT01887951 | Feb → Aug 2014 | — | Singapore General Hospital | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07046572 | Jul → Dec 2025 overdue | endometrial polyp, uterine inflammatory disease | Mount Sinai Hospital, Canada | Recruiting | No outcome recorded |
| — | NCT04292808 | Jul 2020 → Jul 2021 | — | Verso Surgery Centre | Withdrawn | No outcome recorded |
| — | NCT03927729 | Jun 2019 → Mar 2020 | — | University Hospital, Tours | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06750302 Comparator | Nov 2024 → Apr 2026 overdue | chronic rhinosinusitis | St. Paul's Hospital, Canada | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03894800 Comparator | Apr → Oct 2019 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00524927 Comparator | Sep 2007 → Nov 2009 | — | Medical Developments International Limited | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06899724 Comparator | Jun → Dec 2025 overdue | — | Dr. John A. Thiel Medical Professional Corporation | Not yet recruiting | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | methoxyflurane | “Inhaled methoxyflurane (Penthrox) is a potential agent for early administration of analgesia by EAS.” NCT01887951 ↗30“Methoxyflurane (MOF) is a halogenated hydrocarbon volatile general anesthetic” NCT06899724 ↗ |
| Known as | Analgizer | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | Anecotan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | DA-759 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | Inhalan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | MEOF | “Methoxyflurane (MEOF) is self-administered by a handheld device (the Penthrox inhaler), which is licensed in Australia for the relief of pain associated with short surgical procedures.” PMID 24644183 ↗ Jun 20131“Low dose methoxyflurane, (MEOF)is a inhaled, self-administered non-opioid analgesic” NCT04412642 ↗ |
| Known as | Methoxiflurane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | Metofane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | Metoxiflurano | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | MOF | “Methoxyflurane (MOF) is a halogenated hydrocarbon volatile general anesthetic” NCT06899724 ↗ |
| Known as | NSC-110432 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | Penthrane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Known as | Penthrox | “Methoxyflurane (Penthrox) is an inhaled analgesic that has been widely used in Australia and New Zealand for trauma-related pain management for over 30 years and was approved...” NCT06750302 ↗10“The use of inhaled methoxyflurane (Penthrox) has been shown to provide appropriate and effective analgesia for ambulatory care settings” NCT06899724 ↗ “Metoxyflurane (Penthrox®) do not have these adverse effects (hypotension and respiration depression).” NCT03894800 ↗ “Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma” NCT01420159 ↗ “an alternative solution using methoxyflurane (Penthrox®) could be considered.” NCT06495372 ↗ “Penthrox is a brand name for a drug called methoxyflurane.” NCT07192198 ↗ “Penthrox is a brand name for a drug called methoxyflurane.” NCT07017452 ↗ “low dose methoxyflurane (PENTHROX®)” NCT04292808 ↗ “Drug: Methoxyflurane - Penthrox” NCT04476173 ↗ “Penthrox® (Methoxyflurane)” NCT03798899 ↗ |
| Known as | Pentrane | ChEMBL registry synonym — accepted as the source's own label CHEMBL1341 ↗ |
| Modality | Small molecule | “It belongs to the fluorinated hydrocarbon group of volatile anaesthetics.” NCT03256903 ↗ |
| Route | Inhaled | “Methoxyflurane (MEOF) is self-administered by a handheld device (the Penthrox inhaler), which is licensed in Australia for the relief of pain associated with short surgical procedures.” PMID 24644183 ↗ Jun 2013 |